Nedosiran in primary hyperoxaluria subtype 3: results from a phase I, single-dose study (PHYOX4)

[1]  F. Modersitzki,et al.  Healthcare utilization, quality of life, and work productivity associated with primary hyperoxaluria: a cross-sectional web-based US survey , 2023, Urolithiasis.

[2]  J. Lieske,et al.  PHYOX2: A Pivotal Randomized Study of Nedosiran in Primary Hyperoxaluria Type 1 or 2. , 2022, Kidney international.

[3]  M. Stoller,et al.  Perspectives in primary hyperoxaluria — historical, current and future clinical interventions , 2021, Nature Reviews Urology.

[4]  B. Hoppe,et al.  Safety, pharmacodynamics, and exposure-response modeling results from a first in human phase 1 study of nedosiran in primary hyperoxaluria. , 2021, Kidney international.

[5]  J. Lieske,et al.  Primary Hyperoxaluria Type 3 Can Also Result in Kidney Failure: A Case Report. , 2021, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[6]  M. Zaniew,et al.  A report from the European Hyperoxaluria Consortium (OxalEurope) Registry on a large cohort of patients with primary hyperoxaluria type 3. , 2021, Kidney international.

[7]  J. Lieske,et al.  Clinical characterization of primary hyperoxaluria type 3 in comparison to types 1 and 2: a retrospective cohort study. , 2021, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[8]  W. Lowther,et al.  Endpoints for Clinical Trials in Primary Hyperoxaluria. , 2020, Clinical journal of the American Society of Nephrology : CJASN.

[9]  D. Wattenberg,et al.  Primary Hyperoxaluria: The Patient and Caregiver Perspective. , 2020, Clinical journal of the American Society of Nephrology : CJASN.

[10]  R. Holmes,et al.  Reduction in urinary oxalate excretion in mouse models of Primary Hyperoxaluria by RNA interference inhibition of liver lactate dehydrogenase activity. , 2019, Biochimica et biophysica acta. Molecular basis of disease.

[11]  Yanhan Li,et al.  Mutation Hot Spot Region in the HOGA1 Gene Associated with Primary Hyperoxaluria Type 3 in the Chinese Population , 2019, Kidney and Blood Pressure Research.

[12]  Guofeng Xu,et al.  Nine novel HOGA1 gene mutations identified in primary hyperoxaluria type 3 and distinct clinical and biochemical characteristics in Chinese children , 2019, Pediatric Nephrology.

[13]  B. Hoppe,et al.  Metabolic profile and impact of diet in patients with primary hyperoxaluria , 2018, International Urology and Nephrology.

[14]  E. Salido,et al.  Specific Inhibition of Hepatic Lactate Dehydrogenase Reduces Oxalate Production in Mouse Models of Primary Hyperoxaluria , 2018, Molecular therapy : the journal of the American Society of Gene Therapy.

[15]  Lisa E. Vaughan,et al.  Predictors of Incident ESRD among Patients with Primary Hyperoxaluria Presenting Prior to Kidney Failure. , 2016, Clinical journal of the American Society of Nephrology : CJASN.

[16]  J. Bacchetta,et al.  Renal function can be impaired in children with primary hyperoxaluria type 3 , 2015, Pediatric Nephrology.

[17]  J. Lieske,et al.  Phenotype-Genotype Correlations and Estimated Carrier Frequencies of Primary Hyperoxaluria. , 2015, Journal of the American Society of Nephrology : JASN.

[18]  B. Hoppe.  An update on primary hyperoxaluria , 2012, Nature Reviews Nephrology.

[19]  Susan L. Furth,et al.  Improved equations estimating GFR in children with chronic kidney disease using an immunonephelometric determination of cystatin C , 2012, Kidney international.

[20]  W. Haley,et al.  Primary hyperoxaluria type III gene HOGA1 (formerly DHDPSL) as a possible risk factor for idiopathic calcium oxalate urolithiasis. , 2011, Clinical journal of the American Society of Nephrology : CJASN.

[21]  C. Charon,et al.  Mutations in DHDPSL are responsible for primary hyperoxaluria type III. , 2010, American journal of human genetics.

[22]  L. Stevens,et al.  Estimating GFR using the CKD Epidemiology Collaboration (CKD-EPI) creatinine equation: more accurate GFR estimates, lower CKD prevalence estimates, and better risk predictions. , 2010, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[23]  P. Cochat,et al.  Primary hyperoxaluria. , 2013, The New England journal of medicine.